AVITA Medical, Inc. (RCEL) Gross Margin (2018 - 2026)

AVITA Medical (RCEL) has reported Gross Margin for 9 consecutive years, with 81.87% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin rose 70.0% year-over-year to 81.87%; the trailing twelve-month figure through Jun 2026 stood at 40.82% (down 4346.0% YoY), and the FY2025 full-year result was 82.13%, down 371.0% from the prior year.
• Gross Margin rose to 81.87% in Q2 2026 per RCEL's latest filing, from 15.56% in the prior quarter.
• Across five years, Gross Margin topped out at 87.61% in Q4 2024 and bottomed at 15.56% in Q4 2025.
• Historically, Gross Margin has averaged 79.44% across 5 years, with a median of 83.94% in 2023.
• The sharpest annual moves came in 2023 and 2025: Gross Margin jumped 778 bps in 2023, then tumbled 7206 bps in 2025.
• Over 5 years, Gross Margin stood at 85.75% in 2022, then grew by 2 bps to 87.35% in 2023, then climbed by 0 bps to 87.61% in 2024, then sank by 82 bps to 15.56% in 2025, then jumped by 426 bps to 81.87% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 81.87%, 15.56%, and 81.32% for Q2 2026, Q4 2025, and Q3 2025 respectively.